Patents by Inventor Tod M. Woolf

Tod M. Woolf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNA INTERFERENCE IN SKIN INDICATIONS
    Publication number: 20170009239
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Application
    Filed: February 11, 2016
    Publication date: January 12, 2017
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia
  • REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
    Publication number: 20160244765
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.
    Type: Application
    Filed: September 25, 2015
    Publication date: August 25, 2016
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • RNA interference in dermal and fibrotic indications
    Patent number: 9340786
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: May 17, 2016
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
  • REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
    Publication number: 20160130578
    Abstract: The present invention relates to methods for in vivo administration of sd-rxRNA molecules.
    Type: Application
    Filed: June 2, 2015
    Publication date: May 12, 2016
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • INHIBITION OF MAP4K4 THROUGH RNAI
    Publication number: 20160115484
    Abstract: RNAi constructs directed to MAP4K4 that demonstrate unexpectedly high gene silencing activities, and uses thereof are disclosed. The blunt-ended constructs have a double-stranded region of 19-49 nucleotides. The constructs have selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the strands may be modified (e.g., one or both ends of the sense strand is modified by 2?-O-methyl groups), such that the construct is not cleaved by Dicer or other RNAse III, the antisense strand may also be modified by a 2?-O-methyl group at the penultimate 5?-end nucleotide to greatly reduce off-target silencing.
    Type: Application
    Filed: June 2, 2015
    Publication date: April 28, 2016
    Inventors: Tod M. Woolf, Joanne Kamens, Anastasia Khvorova, William Salomon
  • RNA INTERFERENCE IN OCULAR INDICATIONS
    Publication number: 20160115482
    Abstract: The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.
    Type: Application
    Filed: June 2, 2015
    Publication date: April 28, 2016
    Inventors: Lyn Libertine, Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia, Pamela A. Pavco
  • RNA interference in skin indications
    Patent number: 9303259
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: April 5, 2016
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia
  • Reduced size self-delivering RNAi compounds
    Patent number: 9175289
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: November 3, 2015
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • RNA interference in ocular indications
    Patent number: 9095504
    Abstract: The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: August 4, 2015
    Inventors: Lyn Libertine, Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • Reduced size self-delivering RNAi compounds
    Patent number: 9080171
    Abstract: The present invention relates to methods for in vivo administration of sd-rxRNA molecules.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: July 14, 2015
    Assignee: RXi Parmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • Inhibition of MAP4K4 through RNAI
    Patent number: 9074211
    Abstract: RNAi constructs directed to MAP4K4 that demonstrate unexpectedly high gene silencing activities, and uses thereof are disclosed. The blunt-ended constructs have a double-stranded region of 19-49 nucleotides. The constructs have selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the strands may be modified (e.g., one or both ends of the sense strand is modified by 2?-O-methyl groups), such that the construct is not cleaved by Dicer or other RNAse III, the antisense strand may also be modified by a 2?-O-methyl group at the penultimate 5?-end nucleotide to greatly reduce off-target silencing.
    Type: Grant
    Filed: November 19, 2009
    Date of Patent: July 7, 2015
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Tod M. Woolf, Joanne Kamens, Anastasia Khvorova, William Salomon
  • REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
    Publication number: 20140364482
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.
    Type: Application
    Filed: May 15, 2014
    Publication date: December 11, 2014
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • PROGRAMMABLE LIQUID CONTAINERS
    Publication number: 20140346063
    Abstract: The invention relates to liquid containers comprising a plurality of sealed additive chambers in communication with a vessel tillable with a liquid. The additive chambers comprise independently selected additives that may be added to a liquid in the container at the option of the user. The user can manually open the additive chambers of their choice and release the additive into a liquid in the vessel without destroying the integrity of the container. In this manner, the liquid containers are programmable by the users and various aspects of the liquid in the container, such as color and/or flavor, is controlled by the user.
    Type: Application
    Filed: August 5, 2014
    Publication date: November 27, 2014
    Inventors: Tod M. WOOLF, Andrew S. Marks, Glenn Wachler, Scott Woolf
  • RNA INTERFERENCE IN SKIN INDICATIONS
    Publication number: 20140315974
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Application
    Filed: December 12, 2013
    Publication date: October 23, 2014
    Applicant: RXI PHARMACEUTICALS CORPORATION
    Inventors: ANASTASIA KHVOROVA, WILLIAM SALOMON, JOANNE KAMENS, DMITRY SAMARSKY, TOD M. WOOLF, PAMELA A. PAVCO, JAMES CARDIA
  • Phagocytic cell delivery of RNAI
    Patent number: 8815818
    Abstract: The present invention provides a particulate delivery system for delivering an RNAi construct to phagocytic cells such as macrophages, comprising various configurations of a complex comprising a phagocytic cell-targeting moiety and an RNAi construct. The invention further provides methods of making the delivery system, and their uses, such as treating phagocytic cell-associated disease conditions.
    Type: Grant
    Filed: July 17, 2009
    Date of Patent: August 26, 2014
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Dmitry Samarsky, Tod M. Woolf
  • Reduced size self-delivering RNAi compounds
    Patent number: 8796443
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: August 5, 2014
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • ANTIBODY SCREENING METHODS
    Publication number: 20140113831
    Abstract: Provided are methods and compositions for the production of novel antibodies that bind specifically to a target anti gen. These methods and compositions are particularly useful for producing antibodies having the antigen binding specificity of a reference antibody but with improved properties (e.g., binding affinity, immunogenicity, and thermodynamic stability) relative to the reference antibody.
    Type: Application
    Filed: March 14, 2012
    Publication date: April 24, 2014
    Applicant: X-BODY, INC.
    Inventors: Yan Chen, Tod M. Woolf, Richard W. Wagner
  • INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
    Publication number: 20140113950
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.
    Type: Application
    Filed: March 24, 2011
    Publication date: April 24, 2014
    Applicant: RXI PHARMACEUTICALS CORPORATION
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
  • RNA interference in skin indications
    Patent number: 8664189
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: March 4, 2014
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia
  • RNA INTERFERENCE IN OCULAR INDICATIONS
    Publication number: 20130131142
    Abstract: The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.
    Type: Application
    Filed: March 24, 2011
    Publication date: May 23, 2013
    Inventors: Lyn Libertine, Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia